CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company has conducted its First Human Clinical Study with its EOS Peripheral vascular occlusion device. The study involved six male patients who had conditions related to venous peripheral disease, known as varicocele. The patients were infertile and suffered pain in the low pelvic area requiring venous occlusion of their spermatic or gonadal veins. The trial was pivotal in meeting the Company’s goals, with a reported 100% acute procedural and clinical success providing a predictable, immediate occlusion of all targeted blood vessels. The study demonstrated the device’s accuracy, safety and effectiveness.
